XML 68 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies - Additional Information (Detail)
€ in Millions
 1 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2022
USD ($)
Nov. 09, 2022
USD ($)
Jun. 02, 2022
USD ($)
Aug. 05, 2021
USD ($)
Jul. 21, 2021
USD ($)
Aug. 21, 2018
USD ($)
Sep. 01, 2013
USD ($)
Apr. 01, 2013
USD ($)
Jul. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Aug. 31, 2012
USD ($)
Dec. 31, 2010
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2017
USD ($)
Aug. 21, 2023
USD ($)
Dec. 31, 2022
EUR (€)
Jul. 08, 2021
USD ($)
Aug. 31, 2019
USD ($)
Jul. 31, 2008
USD ($)
Feb. 28, 2005
USD ($)
Commitment And Contingencies [Line Items]                                                  
Damages assessment                         $ 235,500,000                        
Annual sales at the time of settlement                         700,000,000                   $ 350,000,000    
Annual sales of Effexor           $ 2,600,000,000                                      
Annual sales of Lamictal                                               $ 2,300,000,000 $ 950,000,000
Annual sales of Niaspan             $ 1,100,000,000 $ 416,000,000                                  
Annual sales of Actos                     $ 2,800,000,000 $ 3,700,000,000                          
Annual sales of Acto plus                     $ 430,000,000 $ 500,000,000                          
Litigation settlement amount                   $ 4,250,000,000                              
Annual Sales Of Sensipar                                   $ 1,400,000,000              
Litigation settlement amount awarded distribution period                   13 years                              
Annual sales of Copaxone                               $ 373,000,000                  
Generic modafinil, and imposed fines amount $ 4,186,000,000                       4,905,000,000   $ 4,186,000,000           € 60.5        
Loss Contingency Accrual, Provision       $ 235,500,000                                          
Annual sales of the time of settlement of viread                         582,000,000                        
Annual sales of the time of settlement of Truvada                         2,400,000,000                        
Annual sales of the time of settlement of Atripla                         2,900,000,000                        
Annual sales of the time of New launch of viread                                     $ 728,000,000            
Annual sales of the time of New launch of Truvada                                 $ 2,100,000,000                
Annual sales of the time of New launch of Atripla                                 $ 444,000,000                
Annual sales of Colcrys                             $ 187,000,000                    
Litigation Settlement Amount Distributable In Kind                         1,200,000,000                        
Accrual for Environmental Loss Contingencies                         $ 300,000                        
Loss Contingencies On Environmental Laws Penalty                                           $ 1,400,000      
Percentage of the litigating subdivisions have chosen to participate in Teva's nationwide settlement                         99.00%                        
Annual Sales Of Revlimid                         $ 3,500,000,000                        
Annual Sales At The Time Of Nuvigil Entered Into First Settlement Of With AN ANDA Filer 300,000,000                                                
Annual Sales Of EpiPen 600,000,000                                                
Loss Contingency Claims Dismissed Value Paid To Each State Proportional To Its Share Of National Population $ 1,000,000,000,000                                                
Percentage Of Share Of The National Population 1.00%                                                
Percentgae of amount in cash settlement                         20.00%                        
Litigation Settlement Amount Distributable in cash                         $ 240,000,000                        
Loss Contingency, Damages Awarded, Value   $ 176,500,000                                              
Maximum [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Damage claimed                         1,000,000,000                        
Nevada [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Loss Contingency, Settlement Agreement Terms                   20 years                              
Payment                   $ 193,000,000                              
Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Fine for Violating the Antitrust Laws [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Other commitment, to be paid, year five                                       $ 135,000,000          
Other commitment to pay for each year                                       22,500,000          
Other commitment                                       225,000,000          
Deferred Prosecution Agreement With U.S. Department of Justice [Member] | Donation of Clotrimazole and Tobramycin [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Other commitment                                       $ 50,000,000          
Four Other Defendants Other Than Teva [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Loss contingency payment         $ 26,000,000,000                                        
Opioid Litigation [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Loss contingency accrual, product liability, undiscounted, to be paid, year five                         370,000,000                        
Loss contingency accrual, product liability, undiscounted, to be paid, year four                         370,000,000                        
Loss contingency accrual, product liability, undiscounted, to be paid, year three                         365,000,000                        
Loss contingency accrual, product liability, undiscounted, to be paid, year two                         418,000,000                        
Loss contingency accrual, product liability, undiscounted, to be paid, year one                         439,000,000                        
Loss contingency aggregate payments paid                         $ 179,000,000                        
Nationwide Settlement [Member] | Four Other Defendants Other Than Teva [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Litigation settlement amount awarded distribution period         18 years                                        
Litigation with U.S. Hospitals and Other Healthcare Providers [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Litigation settlement amount                 $ 126,000,000                                
Litigation settlement amount awarded distribution period                 18 years                                
Product WAC Term                 7 years                                
Product WAC Value                 $ 49,000,000                                
Ontario Teachers Securities Litigation [Member] | Settled Litigation [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Litigation settlement amount     $ 420,000,000                                            
Europe [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Damage claimed                           $ 50,000,000                      
Eosinophilic Esophagitis [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Damage claimed                           200,000,000                      
Eosinophilic Esophagitis [Member] | United States [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Damage claimed                           $ 150,000,000                      
AndroGel Rate at 1% [Member]                                                  
Commitment And Contingencies [Line Items]                                                  
Annual sales at the time of settlement                                             $ 140,000,000